UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $270.35, but opened at $289.84. UCB shares last traded at $287.4875, with a volume of 424 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on UCBJF shares. Wolfe Research started coverage on shares of UCB in a research note on Monday, February 23rd. They issued an “outperform” rating for the company. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a report on Monday, February 16th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy”.

UCB Stock Performance

The company’s fifty day moving average price is $294.94 and its two-hundred day moving average price is $296.12. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.